MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-00809

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025

Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.

Mohty Mohamad, Socié Gerard, Szer Jeff, Niederwieser Dietger, Butler Jason, Wagner-Drouet Eva, Or Reuven, Rovenvald-Zuckerman Tsila, Bozdag Sinem Civriz, Forcade Edouard, Grillo Giovanni, Kröger Nicolaus, Stölzel Friedrich, Russo Domenico, Sanz Jaime, Sarkar Rajendra, Stefanelli Tommaso, Wilke Celine, Zeiser Robert, von Bubnoff Nikolas

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеСравнительное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Approximately 30%-50% of patients develop acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (Allo-HCT), representing a major limitation of this treatment. Although corticosteroids remain the standard first-line therapy for aGVHD, up to 50% of patients become steroid-refractory (SR). REACH2 is a phase III study of ruxolitinib versus best available therapy (BAT) in patients age 12 years and older with SR-aGVHD after Allo-HCT. We present the final efficacy and safety outcomes from REACH2 after 24 months of treatment. Cumulative median (range) duration of response was 167 (22-677) days with ruxolitinib and 106 (10-526) days with BAT. Median overall survival and event-free survival were 10.7 and 8.3 months for ruxolitinib, compared with 5.8 and 4.2 months, respectively, with BAT. Median failure-free survival was significantly longer with ruxolitinib than with BAT (4.86 v 1.02 months, P < .001). Similar numbers of nonrelapse mortality events were observed with ruxolitinib and BAT (72 v 71), and malignancy relapse/progression events remained low across both groups. Numerically higher chronic GVHD rates were noted with ruxolitinib than with BAT from 12 months; however, 95% confidence intervals overlapped. Safety observations were consistent with the primary analysis results. Ruxolitinib provided efficacy advantages over BAT in patients with SR-aGVHD over 24 months.

Для цитирования: Mohty Mohamad, Socié Gerard, Szer Jeff, Niederwieser Dietger, Butler Jason, Wagner-Drouet Eva, Or Reuven, Rovenvald-Zuckerman Tsila, Bozdag Sinem Civriz, Forcade Edouard, Grillo Giovanni, Kröger Nicolaus, Stölzel Friedrich, Russo Domenico, Sanz Jaime, Sarkar Rajendra, Stefanelli Tommaso, Wilke Celine, Zeiser Robert, von Bubnoff Nikolas. Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. DOI: 10.1200/jco-25-00809.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.